Biogen Idec’s (BIIB) second quarter EPS of $1.82 was well above the Zacks Consensus Estimate of $1.56 and the year-ago EPS of $1.35. Higher revenues and a lower share count boosted earnings. Second quarter 2012 revenues increased 17.6% to $1.4 billion, well above the Zacks Consensus Estimate of $1.3 billion.
Biogen increased its earnings outlook for 2012 and now expects EPS to exceed $6.20. Estimates have been on the rise following the release of strong second quarter results. The Zacks Consensus Estimate for 2012 has gone up by 19 cents to $6.33 per share. We are upgrading the stock to Outperform.
Key products Avonex and Tysabri should continue contributing significantly to sales. BG-12 should help drive long-term growth. Meanwhile, Biogen’s restructuring initiative should help drive the bottom line. We are also pleased with Biogen’s efforts to streamline its pipeline.
To read this article on Zacks.com click here.
Zacks Investment Research
